End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Region (APAC, North America, MEA, Europe, Latin America), And Segment Forecasts, 2022 - 2030

Report Overview 

The global end-stage renal disease market size was valued at USD 87.07 billion in 2021 and is anticipated to grow at a compound annual growth rate (CAGR) of 12.9% during the forecast period. An increasing number of patients suffering from kidney failure and the introduction of technologically advanced products, such as low-maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the market. In addition, the COVID-19 pandemic has resulted in significant demand for dialysis globally. Owing to this, the market has witnessed regulatory support from various government authorities and a rise in financial incentives. These factors contribute to the positive growth of the end stage renal disease market (ESRD) market. The pandemic has resulted in an increased demand for home dialysis across the globe.

People suffering from diabetes and ESRD are prone to COVID-19 complications as compared to healthy individuals. Each country is taking care to ensure the safety of patients amid the crisis. The CDC, for instance, has issued guidelines, Interim Additional Guidance for Infection Prevention and Control Recommendations for patients with suspected or confirmed COVID-19 in the outpatient Hemodialysis Facilities, to ensure the safety of hemodialysis patientsMoreover, the demand for dialysis machines for the treatment of AKI increased by 279%. Thereby, the firms are increasing their capacity to supply RRT equipment in COVID-19-affected areas. Thus, a pool of equipment was developed that could be quickly sent to places where there was greater demand.

For instance, in April 2020, FMCNA established the National Intensive Renal Care Reserve, which comprised devices that can deliver CRRT, IHD, and SLED/PIRRT depending on patient’s and institution’s requirements.Any conditions that cause reduced kidney function lead to Chronic Kidney Disease(CKD), which may develop over a period and lead to ESRD where the kidney can no longer function on its own. It is also termed as kidney failure. Factors contributing to the formation of ESRD are hypertension, diabetes, smoking, and the geriatric population. The most common cause is diabetes, whereas hypertension (high blood pressure) is the second-most frequent cause of ESRD. The treatment of ESRD/CKD includes kidney transplantation or dialysis to stay alive.

CKDis one of the major reasons for the high incidence of kidney failure. According to the National Kidney Foundation (NKD), approx. 10% of the global population suffers from CKD and millions of individuals die each year. As per the NKD estimation, the geriatric population suffers in developing countries, such as China and India.Thenumber of patients continues to increase at a rate of 5-7% per year and receive treatment with a kidney transplant or dialysis to stay alive. Chronic kidney disease is estimated to be more common in women than men (15%vs 12%).An increasing number of patients suffering from hypertension and diabetes are other factors driving the overall market growth.

Approximately, one-third of the population living with diabetes develop CKD, and it is the most common cause of end-stage kidney disease. Hypertension is mainly caused due to high blood pressure, which significantly also increases the risk of ESRD. According to the WHO facts 2019, around 1.13 billion people worldwide have hypertension. In the year 2014–2016, diabetes and hypertension were responsible for nearly 75% of kidney failure. Diabetes is the primary cause of advanced kidney disease, followed by hypertension, which is estimated to affect around 1 billion individuals globally. Thus, the increasing number of patients suffering from hypertension and diabetes is majorly driving the market growth.

Regions, such as Africa, China, the Rest of Asia Pacific, the U.S., Taiwan, Japan, Germany, France, and Belgium, have witnessed the highest prevalence of ESRD in recent years. As per the estimation of the Centers for Disease Control and Prevention (CDC) report 2016, in the U.S., around 125,000 people received treatment for ESRD, whereas approximately 726,000 were on dialysis or living with a kidney transplant.Furthermore, it also reported that around 80 million people, which is around 1 in 3 American adults are at risk of CKD and it is the ninth leading cause of death in the U.S. Similarly, as per the report published by NKF in 2017, it is estimated that the number of cases of renal failure will increase, especially in developing countries, such as China and India, in the elderly people, since these patients are more prone to renal problems.

The number of patients continues to increase at a rate of 5-7% per year and receive treatment with a kidney transplant or dialysis to stay alive. Therefore, such a high prevalence of ESRD is anticipated to boost the market growth during the forecast period.The increasing incidence of renal failure in developed and developing countries has driven the launch of technologically advanced products in the market. For instance, in February 2014, the first human clinical trials of blood purification technologies for designing Wearable Artificial Kidney 2.0 was approved by the U.S. FDA. This innovation is intended to obtain satisfactory and effective results from kidney failure patients. Thus, technological advancement in the treatment of renal failure is another factor expediting the overall market growth.

Furthermore, the presence of a large number of hospitals in the U.S., coupled with a well-developed healthcare infrastructure, is another factor contributing to market growth. For instance, according to the American Hospital Association, there were 6,090 community hospitals, 208 federal government hospitals, and 625 nonfederal psychiatric hospitals in the U.S. Significant increase in the number of hospitals and hospital admissions for AKI is boosting the demand for dialysis as well as transplant, thereby propelling the market growth. Moreover, with the rising prevalence of ESRD, the number of dialysis clinics and treatment centers is growing. For instance, in 2020, there were around 7,500 dialysis clinics in the U.S. This factor is expected to positively impact market growth.

Treatment Insights

The dialysis segment dominated the market in 2021 and accounted for the maximum share of more than 77.00%of the total revenue. The segment is also expected to grow at the highest CAGR during the forecast period. Dialysis is more convenient and easier to obtain for a patient with ESRD and the whole process can be done at a dialysis center or home. Moreover, patients don’t have to depend on donor organs, which are available in a very limited number compared to dialysis equipment. Patients in developing, highly populous, or low-income countries can only obtain dialysis as compared to transplantation procedures.

Thus, the benefits offered by dialysis are expected to fuel the market growth. In addition, dialysis is of two types, peritoneal dialysis, and hemodialysis. Hemodialysisis the most widely used procedure in countries, such as China and Japan.Growing awareness about various kidney failure diseases and unhealthy lifestyle is also among the key factors driving the market growth. DaVita Inc., a public community, and other related organizations are committed to raise global awareness regarding kidney diseases.

These organizations arrange awareness education programs, such as kidney smart classes, in which, kidney care experts provide education about reasons for kidney diseases, lifestyle choices, CKD basics, and healthy diets as well as the nutrition information. The National Institute of Health (NIH), has declared the month of March as National Kidney Month to help raise awareness regarding kidney diseases. Thus, the presence of numerous awareness initiatives is expected to result in the growth of patients willing to test for kidney failure. A growing patient population with CKD shall therefore opt for peritoneal dialysis or hemodialysis, which will further increase the demand for ESRD treatment.

Regional Insights

Asia Pacific dominated the regional market in 2021 and accounted for the largest revenue share of more than 37.00% due to increasing healthcare spending, various government initiatives & awareness campaigns regarding CKD, availability of technologically advanced products, and the presence of newly-established state-of-the-art healthcare facilities in the region. High blood pressure and diabetes are the major risks of developing kidney disease. The Asia Pacific region is estimated to have the largest population of diabetes and hypertension patients worldwide, closely followed by Africa.

The Asia Pacific region is also expected to grow at the highest CAGR during the forecast period due to the factors, such as growth in the aging population, various lifestyle stress, a large population base, improving quality of diagnosis, and growing patient affordability. In recent years, China has proven to be an attractive market for medical devices. In March 2019, the Chinese government reduced the Value Added Tax (VAT) for medical manufacturing companies from 13.3% to 13.0%. This was likely to benefit domestic manufacturers of medical equipment, to offset the slowdown caused due to U.S.-China trade war.

Several companies, local and international, are trying to capture this opportunity by launching new & affordable products in the market. Such strategic initiatives undertaken by various companies to expand their businesses in untapped markets have led to several business transactions in the country, thereby contributing to market growth.Middle East & Africa is estimated to closely follow Asia Pacific in terms of CAGR. The African-Middle East ethnicity has been observed to be the most prone to CKD among global populations. The incidence rate for CKD among African-Middle Eastern countries stands at 18-23% of the total population, which is significantly higher than the global population.

Socioeconomic factors, such as income and access to modern facilities, have led to extensive changes in the lifestyle of people, thus leading to lifestyle-related diseases, such as obesity, cancer, and heart disease. For instance, as per the International Diabetes Federation, 55 million adults were living with diabetes in International Diabetes Federation Middle East and North Africa (IDF MENA) region in 2019, and the number is estimated to increase to 108 million by 2045.

Key Companies & Market Share Insights

The key market players are focusing on the launch of innovative types of products and accessories, growth strategies, and technological advancements. For instance, in April 2021, Baxter received the U.S. FDA Emergency Use Authorization (EUA) for its Oxiris Blood Purification Filter set for COVID-19 patients admitted to the ICU with confirmed/imminent respiratory failure in need of blood purification therapy.

In October 2019, Fresenius Medical Care received breakthrough device designation by the U.S. FDA for its new hemodialysis machine that aims to stop blood clotting without the use of any medication. In addition, a few key players are introducing technologically advanced products to achieve a competitive advantage in the industry. Advancements in the area of the ESRD devices market are anticipated to boost the market growth over the forecast period. Some prominent players operating in the global end stage renal disease treatment market include:

• Nipro Corp.

• Fresenius Medical Care AG & Co. KGaA

• Baxter International, Inc.

• Medtronic Plc

• B. Braun Melsungen AG

• BD

• Asahi Kasei Medical Co., Ltd.

• Cantel Medical

• Nikkiso Co., Ltd.

• JMS Co. Ltd.

End Stage Renal Disease Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global end stage renal disease market report based on treatment and region:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Transplant

  • Dialysis

    • Peritoneal Dialysis

    • Hemodialysis

    • Wearable Artificial Kidney

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE